文献速递妇科

荷兰细胞学筛查与高危人乳头瘤病毒筛查宫颈癌项目的获益与负担比较

Benefit and burden in the Dutch cytology-based vs high-risk human papillomavirus-based cervical cancer screening program.
PubMed 文献 · Am J Obstet Gynecol · 2020-08-13

该回顾性队列研究比较荷兰2014-2015年细胞学筛查与2017-2018年高危人乳头瘤病毒(hrHPV)筛查项目的转诊率、高级别宫颈上皮内瘤变检出率、过度诊断和过度治疗。hrHPV筛查转诊率从2.5%升至4.2%,CIN2+检出率增加46.2%,过度诊断增加143.4%,过度治疗率相似;自采样者CIN2+检出风险高于医生采样者(OR 1.38)。

要点

  • hrHPV筛查较细胞学筛查转诊率从2.5%升至4.2%(+70.2%)。
  • hrHPV筛查CIN2+检出率增加46.2%,过度诊断增加143.4%。
  • 自采样者CIN2+检出风险高于医生采样者(OR 1.38,95%CI 1.20-1.59)。

核心结论

  • 与细胞学筛查相比,hrHPV筛查增加高级别宫颈上皮内瘤变检出,每10万妇女多462例CIN2+,但每10万妇女多850例侵袭性诊断提示CIN1或更轻。

研究设计与样本

  • 在荷兰基于人群的宫颈癌筛查项目内开展的回顾性队列研究,纳入2014-2015年(细胞学筛查)和2017-2018年(hrHPV筛查)因转诊接受阴道镜检查的筛查妇女,数据来自荷兰病理登记库(PALGA)。
  • 细胞学筛查组19109例,hrHPV筛查组26171例。

主要发现

  • 转诊率从细胞学筛查的2.5%升至hrHPV筛查的4.2%(+70.2%)。
  • hrHPV筛查CIN2+检出率增加46.2%,CIN3+检出率增加32.2%,宫颈癌检出率增加31.0%,过度诊断增加143.4%。
  • 两个筛查时期过度治疗率相似。
  • hrHPV筛查转诊对CIN2+检出的阳性预测值为34.6%,细胞学筛查为40.2%。
  • 自采样者较医生采样者CIN2+检出风险更高(OR 1.38,95%CI 1.20-1.59),接受治疗风险更高(OR 1.31,95%CI 1.16-1.48)。

关键数值与推荐

  • 转诊率:细胞学筛查2.5% vs hrHPV筛查4.2%(+70.2%)。
  • CIN2+检出率增加46.2%,CIN3+检出率增加32.2%,宫颈癌检出率增加31.0%,过度诊断增加143.4%。
  • 转诊对CIN2+的阳性预测值:hrHPV筛查34.6% vs 细胞学筛查40.2%。
  • 自采样 vs 医生采样:CIN2+检出OR 1.38(95%CI 1.20-1.59),治疗OR 1.31(95%CI 1.16-1.48)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In 2017, the Dutch cervical cancer screening program had replaced the primary cytology-based screening with primary high-risk human papillomavirus-based screening, including the opportunity to participate through self-sampling. Evaluation and balancing benefit (detection of high-grade cervical intraepithelial neoplasia) and burden of screening (unnecessary referrals, invasive diagnostics, and overtreatment) is needed. OBJECTIVE: This study aimed to compare the referral rates, detection of high-grade cervical intraepithelial neoplasia, overdiagnosis, and overtreatment in the new high-risk human papillomavirus-based screening program, including physician-sampled and self-sampled material, with the previous cytology-based screening program in the Netherlands. STUDY DESIGN: A retrospective cohort study was conducted within the Dutch population-based cervical cancer screening program. Screenees with referrals for colposcopy between 2014 and 2015 (cytology-based screening) and 2017 and 2018 (high-risk human papillomavirus-based screening) were included. Data were retrieved from the Dutch Pathology Registry (PALGA) and compared between the 2 screening programs. The main outcome measures were referral rate, detection of high-grade cervical intraepithelial neoplasia or worse, overdiagnosis (cervical intraepithelial neoplasia grade 1 or less in the histologic specimen), and overtreatment (cervical intraepithelial neoplasia grade 1 or less in the treatment specimen). RESULTS: Of the women included in the study, 19,109 received cytology-based screening, and 26,171 received high-risk human papillomavirus-based screening. Referral rates increased from 2.5% in cytology-based screening to 4.2% in high-risk human papillomavirus-based screening (+70.2%). Detection rates increased to 46.2% for cervical intraepithelial neoplasia grade 2 or worse, 32.2% for cervical intraepithelial neoplasia grade 3 or worse, and 31.0% for cervical cancer, and overdiagnosis increased to 143.4% with high-risk human papillomavirus-based screening. Overtreatment rates were similar in both screening periods. The positive predictive value of referral for detection of cervical intraepithelial neoplasia grade 2 or worse in high-risk human papillomavirus-based screening was 34.6% compared with 40.2% in cytology-based screening. Women screened through self-sampling were at higher risk of cervical intraepithelial neoplasia grade 2 or worse detection (odds ratio, 1.38; 95% confidence interval, 1.20-1.59) and receiving treatment (odds ratio, 1.31; 95% confidence interval, 1.16-1.48) than those screened through physician-sampling. CONCLUSION: Compared with cytology-based screening, high-risk human papillomavirus-based screening increases detection of high-grade cervical intraepithelial neoplasia, with 462 more cervical intraepithelial neoplasia grade 2 or worse cases per 100,000 women but at the expense of 850 more cases per 100,000 women with invasive diagnostics indicating cervical intraepithelial neoplasia grade 1 or less.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Loopik DL, Koenjer LM, Siebers AG, et al. Benefit and burden in the Dutch cytology-based vs high-risk human papillomavirus-based cervical cancer screening program. Am J Obstet Gynecol. 2020. PMID: 32800820. doi:10.1016/j.ajog.2020.08.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。